3 Express Logistics Company, Pharmaceutical Intermediates Maker and Motorcycles and Three Wheelers Maker Stocks With a Strong Future Roadmap: Blue Dart Express, Divi's Laboratories and Bajaj Auto

Express logistics, pharma and motorcycle stocks offer a focused view of a sector where demand keeps widening. Blue Dart Express, Divi's Laboratories and Bajaj Auto cover an express logistics company, a pharmaceutical intermediates maker and a motorcycles and three wheelers maker.

This list covers three express logistics, pharma and motorcycle stocks with complete current figures: Blue Dart Express, Divi's Laboratories and Bajaj Auto. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Express Logistics, Pharma and Motorcycle Stocks?

Express logistics, pharma and motorcycle stocks are listed companies that deliver parcels and express cargo across India and abroad, make active pharmaceutical ingredients and intermediates, and build motorcycles, three wheelers and electric vehicles. Their earnings depend on parcel volumes, medicine ingredient demand and vehicle sales.

Express Logistics, Pharma and Motorcycle Stocks at a Glance

On valuation, Blue Dart Express trades at a P/E below the industry P/E, while Divi's Laboratories and Bajaj Auto trade above it, which reflects the growth the market already expects. Readers comparing express logistics, pharma and motorcycle stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Express Logistics, Pharma and Motorcycle Stocks Have a Strong Roadmap in India?

Express logistics, pharma and motorcycle stocks have a strong roadmap in India because fast growth of online shopping, steady demand for essential medicines and rising exports of vehicles keep widening the market for these companies.

• Express logistics. Online shopping needs fast delivery.
• Pharma intermediates. Medicine makers need reliable supply.
• Motorcycles and three wheelers. Riders and traders buy more vehicles.

Why Blue Dart Express Features Among These Express Logistics, Pharma and Motorcycle Stocks

Among the express logistics, pharma and motorcycle stocks on this list, Blue Dart Express is India's leading express air and ground parcel company, part of the DHL Group, delivering to a vast number of locations through its own aircraft, vehicles and service centres.

In the June 2026 quarter, revenue grew 15.2% year on year to Rs 1,673 crore, while net profit rose 81.2% to Rs 88.5 crore. Revenue rose from Rs 4,441 crore in FY22 to Rs 6,183 crore in FY26, a compound annual growth rate of 8.6%.

Net profit for FY26 was Rs 247 crore, a net margin of 4.0%. The company has a return on equity of 15.8%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 10,391 crore. The stock trades at a P/E of 36.2, below the industry P/E of 44.9.

Roadmap: The growth of e-commerce and demand for fast, reliable delivery support parcel volumes. The company's network, brand and links with DHL give it an edge in time-sensitive and international shipments.

What to watch: Follow shipment volume growth and the contribution of e-commerce customers.

Why Divi's Laboratories Features Among These Express Logistics, Pharma and Motorcycle Stocks

Among the courier network, custom synthesis and bike maker shares on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Bajaj Auto Features Among These Express Logistics, Pharma and Motorcycle Stocks

Among the three companies on this list, Bajaj Auto makes motorcycles, three-wheelers and electric vehicles, and it sells a large share of its output to export markets across Africa, Latin America and Asia.

Revenue rose from Rs 34,429 crore in FY22 to Rs 65,087 crore in FY26, a compound annual growth rate of 17.3%. Net profit grew from Rs 6,166 crore in FY22 to Rs 10,574 crore in FY26, which works out to a compound annual growth rate of 14.4%.

The company has a return on equity of 27.7%, a debt to equity ratio of 0.58 and a market capitalisation of Rs 277,002 crore. The stock trades at a P/E of 24.0, above the industry P/E of 23.4.

Roadmap: The company is growing its premium motorcycle and electric three-wheeler ranges and widening its export reach. A strong presence in commercial three-wheelers adds steady demand.

What to watch: Follow export volumes, premium motorcycle mix and electric vehicle growth.

Blue Dart Express vs Divi's Laboratories vs Bajaj Auto on Key Financials

The table below sets the three express logistics, pharma and motorcycle stocks side by side on revenue, profit and margin, using reported figures.

Bajaj Auto posts the highest return on equity in this group at 27.7%. Bajaj Auto combines the largest FY26 revenue at Rs 65,087 crore with the fastest revenue growth, a 17.3% compound annual rate. A useful habit with express logistics, pharma and motorcycle stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Express Logistics, Pharma and Motorcycle Stocks

Every theme carries risks that deserve a check before any decision. For these express logistics, pharma and motorcycle stocks, the main points are:

• Cargo volumes. Freight and parcel volumes follow trade and consumption.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Production cycles. Vehicle output can vary with demand.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter express logistics, pharma and motorcycle stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Express Logistics, Pharma and Motorcycle Stocks

Express logistics, pharma and motorcycle stocks reward patient research into demand, execution and financial strength. Blue Dart Express, Divi's Laboratories and Bajaj Auto each have a clear plan to grow. Based on the 12 November 2026 close, Blue Dart Express trades at Rs 4,469.7, Divi's Laboratories at Rs 11,485 and Bajaj Auto at Rs 10,945.

Download the Univest iOS App or Univest Android App to track express logistics, pharma and motorcycle stocks, set price alerts and get research-backed stock ideas.

What are express logistics, pharma and motorcycle stocks?

Ans. Express logistics, pharma and motorcycle stocks are listed companies that deliver parcels and express cargo across India and abroad, make active pharmaceutical ingredients and intermediates, and build motorcycles, three wheelers and electric vehicles. Their earnings depend on parcel volumes, medicine ingredient demand and vehicle sales. This list looks at three of them, Blue Dart Express, Divi's Laboratories and Bajaj Auto, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.

Which express logistics, pharma and motorcycle stocks are covered in this list?

Ans. This list covers Blue Dart Express, Divi's Laboratories and Bajaj Auto. Based on the 12 November 2026 close, Blue Dart Express traded at Rs 4,469.7, Divi's Laboratories at Rs 11,485 and Bajaj Auto at Rs 10,945. Their return on equity ranges from 15.3% to 27.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 17.3%.

Why do express logistics, pharma and motorcycle stocks have a strong future roadmap in India?

Ans. Express logistics, pharma and motorcycle stocks have a strong roadmap in India because fast growth of online shopping, steady demand for essential medicines and rising exports of vehicles keep widening the market for these companies. The main drivers are as follows. Express logistics. Online shopping needs fast delivery. Pharma intermediates. Medicine makers need reliable supply. Motorcycles and three wheelers. Riders and traders buy more vehicles. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Blue Dart Express performed financially?

Ans. Revenue rose from Rs 4,441 crore in FY22 to Rs 6,183 crore in FY26, a compound annual growth rate of 8.6%. Net profit for FY26 was Rs 247 crore, a net margin of 4.0%. In the June 2026 quarter, revenue grew 15.2% year on year to Rs 1,673 crore, while net profit rose 81.2% to Rs 88.5 crore. The company has a return on equity of 15.8%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 10,391 crore. The stock trades at a P/E of 36.2, below the industry P/E of 44.9. Looking ahead, the growth of e-commerce and demand for fast, reliable delivery support parcel volumes. The company's network, brand and links with DHL give it an edge in time-sensitive and international shipments.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Bajaj Auto performed financially?

Ans. Revenue rose from Rs 34,429 crore in FY22 to Rs 65,087 crore in FY26, a compound annual growth rate of 17.3%. Net profit grew from Rs 6,166 crore in FY22 to Rs 10,574 crore in FY26, which works out to a compound annual growth rate of 14.4%. The company has a return on equity of 27.7%, a debt to equity ratio of 0.58 and a market capitalisation of Rs 277,002 crore. The stock trades at a P/E of 24.0, above the industry P/E of 23.4. Looking ahead, the company is growing its premium motorcycle and electric three-wheeler ranges and widening its export reach. A strong presence in commercial three-wheelers adds steady demand.

What risks should investors check before buying express logistics, pharma and motorcycle stocks?

Ans. Investors should check a few risks before buying express logistics, pharma and motorcycle stocks. Cargo volumes. Freight and parcel volumes follow trade and consumption. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of express logistics, pharma and motorcycle stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.